Groups | Age ± SD* | Gender | Education | Living | ||
---|---|---|---|---|---|---|
Female | ≤ 7 yerars | Couple | Comorbidity | Drug use | ||
n (%) | n (%) | n (%) | ± SD* | ± SD* | ||
Municipality | ||||||
Stimulation | 81.6 ± 6.7 | 59(57) | 88(85) | 48(46) | 1.82 ± 1.7 | 4.89 ± 3.3 |
Standard care | 4.89 ± 3.3 | 54(65) | 65(79) | 37(45) | 1.65 ± 1.1 | 5.40 ± 3.9 |
p-value | 0.12 | 0.25 | 0.34 | 0.83 | 0.45 | 0.34 |
Drug | ||||||
Donepezil | 80.80 ± 6.8 | 62(67) | 82(89) | 39(42) | 1.90 ± 1.7 | 5.10 ± 3.3 |
Placebo | 80.85 ± 7.3 | 50(54) | 70(75) | 46(49) | 1.59 ± 1.2 | 5.16 ± 3.8 |
p-value | 0.96 | 0.07 | 0.014 | 0.30 | 0.15 | 0.90 |
Combination | ||||||
Donepezil + stimulation | 81.32 ± 7.0 | 31(60) | 47(90) | 28(54) | 2.02 ± 2.0 | 4.92 ± 2.8 |
Placebo + Standard care | 79.81 ± 8.1 | 22(54) | 29(71) | 19(46) | 1.51 ± 1.1 | 5.41 ± 3.9 |
p-value | 0.34 | 0.57 | 0.015 | 0.47 | 0.14 | 0.48 |
Head to head | ||||||
Stimulation therapy | 81.89 ± 8.3 | 27(53) | 40(78) | 24(47) | 1.61 ± 1.4 | 4.88 ± 3.7 |
Donepezil | 80.17 ± 6.4 | 28(74) | 32(86) | 15(39) | 1.76 ± 1.3 | 5.26 ± 4.0 |
p-value | 0.21 | 0.046 | 0.33 | 0.45 | 0.61 | 0.65 |